Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first half 2025 financial results announcement. The company will release its financial results for the period ending June 30, 2025 after U.S. markets close on August 13, 2025.
A conference call and webcast to discuss the results and business highlights will be held on August 14, 2025, at 8:00 am EDT. The presentation will be accessible through Alvotech's investor portal, with a replay available for 90 days following the event.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata nello sviluppo di medicinali biosimilari, ha programmato l'annuncio dei risultati finanziari per il primo semestre 2025. La societ脿 pubblicher脿 i risultati finanziari relativi al periodo conclusosi il 30 giugno 2025 dopo la chiusura dei mercati statunitensi il 13 agosto 2025.
Una conference call e una webcast per discutere i risultati e i principali sviluppi aziendali si terranno il 14 agosto 2025 alle 8:00 EDT. La presentazione sar脿 accessibile tramite il portale investitori di Alvotech, con una replica disponibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una compa帽铆a biotecnol贸gica global enfocada en el desarrollo de medicamentos biosimilares, ha programado el anuncio de sus resultados financieros del primer semestre de 2025. La empresa publicar谩 sus resultados financieros correspondientes al per铆odo finalizado el 30 de junio de 2025 tras el cierre de los mercados estadounidenses el 13 de agosto de 2025.
Se realizar谩 una llamada conferencia y una transmisi贸n en l铆nea para discutir los resultados y los aspectos destacados del negocio el 14 de agosto de 2025 a las 8:00 am EDT. La presentaci贸n estar谩 disponible a trav茅s del portal de inversores de Alvotech, con una repetici贸n accesible durante 90 d铆as despu茅s del evento.
Alvotech (NASDAQ: ALVO)電� 氚旍澊鞓れ嫓氚�霟� 鞚橃暯頀� 臧滊皽鞐� 欤茧牓頃橂姅 旮�搿滊矊 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 靸侂皹旮� 鞛鞁れ爜 氚滍憸 鞚检爼鞚� 頇曥爼頄堨姷雼堧嫟. 須岇偓電� 2025雲� 6鞗� 30鞚� 膦呺霅� 旮瓣皠鞚� 鞛鞁れ爜鞚� 氙戈淡 鞁滌灔 毵堦皭 頉勳澑 2025雲� 8鞗� 13鞚�鞐� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
瓴瓣臣 氚� 欤检殧 靷梾 雮挫毄鞚� 雲检潣頃橂姅 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼電� 2025雲� 8鞗� 14鞚� 鞓れ爠 8鞁� EDT鞐� 歆勴枆霅╇媹雼�. 氚滍憸 鞛愲電� Alvotech 韴瀽鞛� 韽劯鞚� 韱淀暣 鞝戩啀 臧�電ロ晿氅�, 頄夓偓 頉� 90鞚缄皠 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞝滉车頃╇媹雼�.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale sp茅cialis茅e dans le d茅veloppement de m茅dicaments biosimilaires, a programm茅 l'annonce de ses r茅sultats financiers du premier semestre 2025. La soci茅t茅 publiera ses r茅sultats financiers pour la p茅riode se terminant le 30 juin 2025 apr猫s la cl么ture des march茅s am茅ricains le 13 ao没t 2025.
Une conf茅rence t茅l茅phonique et un webinaire pour discuter des r茅sultats et des faits marquants de l'entreprise auront lieu le 14 ao没t 2025 脿 8h00 EDT. La pr茅sentation sera accessible via le portail investisseurs d'Alvotech, avec une rediffusion disponible pendant 90 jours apr猫s l'茅v茅nement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse f眉r das erste Halbjahr 2025 terminiert. Das Unternehmen wird die Finanzergebnisse f眉r den Zeitraum bis zum 30. Juni 2025 nach B枚rsenschluss in den USA am 13. August 2025 惫别谤枚蹿蹿别苍迟濒颈肠丑别苍.
Eine Telefonkonferenz und ein Webcast zur Besprechung der Ergebnisse und Gesch盲ftshighlights finden am 14. August 2025 um 8:00 Uhr EDT statt. Die Pr盲sentation ist 眉ber das Investorenportal von Alvotech zug盲nglich, mit einer Wiedergabe f眉r 90 Tage nach der Veranstaltung.
- None.
- None.
REYKJAVIK, ICELAND (August 6, 2025) 鈥� Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. 聽Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).聽 Live audio of the conference call will be webcast and available on Alvotech鈥檚 investor portal.
Information on how to access the webcast or participate by conference call is posted on Alvotech鈥檚 investor portal . Specifically, links to access the webcast and instructions to sign in by phone can be found at . The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira庐 (adalimumab) and Stelara庐 (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech鈥檚 commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy鈥檚 (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
Please visit our , and our or follow us on social media on , , , and .
FAQ
When will Alvotech (NASDAQ: ALVO) release its H1 2025 financial results?
What time is Alvotech's H1 2025 earnings conference call?
How can investors access Alvotech's H1 2025 earnings call?
What period will Alvotech's financial results cover?
